.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Julphar
US Army
UBS
Healthtrust
Fuji
McKinsey
Cipla
Express Scripts
Dow

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,084,483

« Back to Dashboard

Which drugs does patent 8,084,483 protect, and when does it expire?


Patent 8,084,483 protects DUZALLO and ZURAMPIC and is included in two NDAs.

This patent has seventy-nine patent family members in thirty-one countries.

Summary for Patent: 8,084,483

Title:Compounds and compositions and methods of use
Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Inventor(s): Quart; Barry D. (Encinitas, CA), Girardet; Jean-Luc (San Diego, CA), Gunic; Esmir (San Diego, CA), Yeh; Li-Tain (Irvine, CA)
Assignee: Ardea Biosciences, Inc. (San Diego, CA)
Application Number:12/324,764
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ironwood Pharms Inc
DUZALLO
allopurinol; lesinurad
TABLET;ORAL209203-001Aug 18, 2017RXYesNo► Subscribe► Subscribe
Ironwood Pharms Inc
DUZALLO
allopurinol; lesinurad
TABLET;ORAL209203-002Aug 18, 2017RXYesYes► Subscribe► Subscribe
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes► Subscribe► Subscribe REDUCTION OF SERUM URIC ACID LEVELS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,084,483

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,173,690Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,283,369Compounds and compositions and methods of use► Subscribe
8,344,012Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,633,232Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,546,437Compounds and compositions and methods of use► Subscribe
8,357,713Compounds and compositions and methods of use► Subscribe
8,242,154Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
8,193,234Compounds, compositions and methods of using same for modulating uric acid levels► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,084,483

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine102826► Subscribe
Taiwan201018463► Subscribe
TaiwanI415840► Subscribe
Taiwan200927733► Subscribe
TaiwanI377200► Subscribe
Taiwan201022216► Subscribe
Tunisia2010000237► Subscribe
Slovenia2217577► Subscribe
Singapore183721► Subscribe
Serbia53569► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Fuji
Healthtrust
Chinese Patent Office
Moodys
McKesson
Johnson and Johnson
Covington
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot